Greg Durm, MD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Greg Durm, MD sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Greg Durm, MD: 4 sponsored US clinical trials, 1 recruiting.
Greg Durm, MD sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NSCLC, Stage I, with 1 trials.
Upper-quartile sponsor footprint
Greg Durm, MD sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
NCT04317534
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
NCT03871153
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
NCT03285321
Phase II Trial of Continuation Therapy in Advanced NSCLC
NCT03083808
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Therapeutic Areas
What is open in the Greg Durm, MD pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: NSCLC, Stage I (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Greg Durm, MD: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Greg Durm, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Greg Durm, MD page
4 registered trials is a research-attention snapshot, not an endorsement of Greg Durm, MD or any single study.
- 1 of Greg Durm, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- NSCLC, Stage I is the condition Greg Durm, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NSCLC, Stage I trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Greg Durm, MD pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.